We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
TELIGAN 중간 결과: Telitacicept, 단백뇨 58.9% 감소 vs 위약 8.8%. 새로운 이중 억제제가 IgA 신병증 시장을 어떻게 변화시키는지 알아보세요.
